L3VLUP
ProSign in

RPRX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RPRXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RPRX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterRPRXLLY
Q3 20207 holders, $1.6bn33 holders, $14.1bn
Q4 20205 holders, $1.9bn29 holders, $17.3bn
Q1 20215 holders, $1.5bn24 holders, $23.0bn
Q2 20218 holders, $1.5bn24 holders, $27.8bn
Q3 20216 holders, $1.4bn31 holders, $29.9bn
Q4 20218 holders, $1.8bn31 holders, $34.7bn
Q1 20228 holders, $1.8bn24 holders, $35.3bn
Q2 202210 holders, $3.2bn33 holders, $42.7bn
Q3 202211 holders, $3.4bn31 holders, $43.4bn
Q4 202217 holders, $3.4bn31 holders, $46.6bn
Q1 202314 holders, $2.9bn33 holders, $44.3bn
Q2 202316 holders, $2.3bn37 holders, $59.6bn
Q3 202314 holders, $1.9bn44 holders, $67.6bn
Q4 202313 holders, $2.1bn45 holders, $73.6bn
Q1 202410 holders, $2.2bn41 holders, $95.3bn
Q2 202412 holders, $1.7bn43 holders, $110bn
Q3 202410 holders, $2.0bn45 holders, $107bn
Q4 202410 holders, $1.6bn46 holders, $93.9bn
Q1 20259 holders, $2.3bn42 holders, $98.4bn
Q2 20259 holders, $2.4bn43 holders, $93.2bn
Q3 202511 holders, $1.9bn39 holders, $86.7bn
Q4 202510 holders, $2.4bn41 holders, $123bn
Q1 202615 holders, $3.1bn39 holders, $106bn
Q2 202615 holders, $3.9bn44 holders, $132bn
RPRX

Royalty Pharma PLC

Holders
15
Reported value
$3.1bn
Buyers
18
Sellers
16

Breadth +2 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
39
Reported value
$106bn
Buyers
25
Sellers
25

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RPRX (4)

Baillie Gifford & Co, Farallon Capital Management LLC, Freestone Grove Partners LP, Quantbot Technologies LP

Only LLY (28)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Artisan Partners LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Schonfeld Strategic Advisors LLC, Soros Fund Management LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →